z-logo
open-access-imgOpen Access
RORα and RORγ expression inversely correlates with human melanoma progression
Author(s) -
Anna A. Brożyna,
Wojciech Jóźwicki,
Cezary Skobowiat,
Anton M. Jetten,
Andrzej Slominski
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.11211
Subject(s) - melanoma , medicine , rar related orphan receptor gamma , orphan receptor , cancer research , retinoic acid , pathology , biology , immune system , immunology , transcription factor , gene , biochemistry , foxp3
The retinoic acid-related orphan receptors (RORs) regulate several physiological and pathological processes, including immune functions, development and cancer. To study the potential role of RORs in melanoma progression, we analysed RORα and RORγ expression in nevi and primary melanomas and non-lesional skin and metastases in relation to melanoma clinico-pathomorphological features. The expression of RORα and RORγ was lower in melanomas than in nevi and decreased during melanoma progression, with lowest levels found in primary melanomas at stages III and IV and in melanoma metastases. Their expression correlated with pathomorphological pTNM parameters being low in aggressive tumors and being high in tumors showing histological markers of good prognosis. Higher nuclear levels of RORα and RORγ and of cytoplasmic RORγ correlated with significantly longer overall and disease free survival time. Highly pigmented melanomas showed significantly lower level of nuclear RORs. This study shows that human melanoma development and aggressiveness is associated with decreased expression of RORα and RORγ, suggesting that RORs could be important in melanoma progression and host responses against the tumor. Furthermore, it suggests that RORα and RORγ might constitute a novel druggable target in anti-melanoma management using tumor suppressor gene therapy restoring their normal functions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here